Minerva anestesiologica
-
Minerva anestesiologica · Dec 1995
Randomized Controlled Trial Clinical Trial[Evaluation of the synergism between ketorolac and morphine in the treatment of postoperative pain].
The aim of the study is to determine what concentration of ketorolac and morphine administered together i.v. achieve best synergic effect between NSAID antiinflammatory and opioids analgesic properties. ⋯ Results suggest a greater synergetic effect between morphine and ketorolac in concentrations used in group 2.
-
Minerva anestesiologica · Dec 1995
Clinical TrialEvaluating the difficult airway. An epidemiological study.
The epidemiological characteristics of 359 difficult intubations resulted from retrospectively collected data in a series of 4.742 individual anaesthetic case records of consecutive adult patients (2392 men, 2350 women) undergoing general anaesthesia for routine surgery. The preoperative assessment of each patient's airway was performed using standardized guidelines. Mandibular length, body weight and mobility of jaw, head and neck were evaluated with simple measurements. ⋯ Large endemic goitre and thalassaemia constitute RFs contributing occasionally to difficult airway. The positive predictive value was 61.5% and 40.9% respectively. The combination of risk-factors had a cumulative impact contributing to the high level of difficulty.
-
Minerva anestesiologica · Dec 1995
Comparative Study Clinical Trial Controlled Clinical Trial[Clinical pharmacology of pipecuronium; a comparative study of its duration of action in balanced anesthesia (propofol/fentanyl) vs isoflurane].
Clinical pharmacology of pipecuronium; a comparative study of its duration of action between balanced (propofol/fentanyl) and isoflurane anesthesia. Pipecuronium duration of action has been compared between patients under balanced (propofol/fentanyl) or 0.8-1 Mac isoflurane anesthesia. T1/TC 10-25-50-75-90% (T1/TC, 10, T1/TC, 25, T1/TC, 50 TOF, 75T1/TC 90) and TOF 10-25-50-75% (TOF 10%, TOF 25%, TOF 50%, TOF 75%) ratios were studied; T1/TC 10-75% (T1/TC 10/75) and TOF 10-75% (TOF 10-75%) recovery times were also derived. ⋯ The presence of isoflurane significantly prolonged recovery times (TOF 10%, from 55 to 70, TOF 25% from 61 to 88, TOF 50% from 75 to 120) in group I (cumulative doses) patients. Recovery times were dose related, while age did influence recovery only at the earlier intervals (T1/TC 10 and 25%). Keeping in mind the limited range of age and dosages, advantages and disadvantages of the drug are discussed, comparing the experimental results with those derived from the literature.